WTAP/IGF2BP3 Mediated M6A Modification of the EGR1/PTEN Axis Regulates the Malignant Phenotypes of Endometrial Cancer Stem Cells

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2024 Jul 23

PMID 39044249

Authors

Bo Wang

Yuting Wang

Wantong Wang

Zihao Wang

Yunzheng Zhang

Xin Pan

Xin Wen

Hongrui Leng

Jing Guo

Xiao-Xin Ma

Affiliations

Soon will be listed here.

Abstract

Endometrial cancer (EC) stem cells (ECSCs) are pivotal in the oncogenesis, metastasis, immune escape, chemoresistance, and recurrence of EC. However, the specific mechanism of stem cell maintenance in EC cells (ECCs) has not been clarified. We found that WTAP and m6A levels decreased in both EC and ECSCs, and that knocking down WTAP promoted ECCs and ECSCs properties, including proliferation, invasion, migration, cisplatin resistance, and self-renewal. The downregulation of WTAP leads to a decrease in the m6A modification of EGR1 mRNA, and it is difficult for IGF2BP3, as an m6A reader, to recognize and bind to EGR1 mRNA that has lost m6A modification, resulting in a decrease in the stability of EGR1 mRNA. A decrease in the EGR1 level led to a decrease of in the expression tumor suppressor gene PTEN, resulting in deregulation and loss of cellular homeostasis and thereby fostering EC stem cell traits. Notably, the enforced overexpression of WTAP, EGR1, and PTEN inhibited the oncogenic effects of ECCs and ECSCs in vivo, and the combined overexpression of WTAP + EGR1 and EGR1 + PTEN further diminished the tumorigenic potential of these cells. Our findings revealed that the WTAP/EGR1/PTEN pathway is important regulator of EC stem cell maintenance, chemotherapeutic resistance, and tumorigenesis, suggesting a novel and promising therapeutic avenue for treating EC.

Citing Articles

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.

Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.

PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.

Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.

Li P, Lin Y, Ma H, Zhang J, Zhang Q, Yan R Cell Death Discov. 2025; 11(1):43.

PMID: 39904996 PMC: 11794895. DOI: 10.1038/s41420-025-02324-z.

S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.

Chai Y, Xiang H, Ma Y, Feng W, Jiang Z, Zhu Q J Exp Clin Cancer Res. 2024; 43(1):304.

PMID: 39551792 PMC: 11571582. DOI: 10.1186/s13046-024-03230-5.

References

Aikins M, Qin Y, Dobson H, Najafabadi A, Lyu K, Xu Y . Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma. J Control Release. 2022; 351:872-882. PMC: 9765445. DOI: 10.1016/j.jconrel.2022.09.061. View

Fortin J, Bassi C, Ramachandran P, Li W, Tian R, Zarrabi I . Concerted roles of PTEN and ATM in controlling hematopoietic stem cell fitness and dormancy. J Clin Invest. 2021; 131(5). PMC: 7919727. DOI: 10.1172/JCI131698. View

Kong F, Li D, Yang H, Ma J, Pan X, Liu H . Preliminary identification of endometrial cancer stem cells in vitro and in vivo. Biochem Biophys Res Commun. 2017; 490(2):506-513. DOI: 10.1016/j.bbrc.2017.06.070. View

Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z . The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021; 6(1):74. PMC: 7897327. DOI: 10.1038/s41392-020-00450-x. View

Zhu T, Hong L, Ling Z . Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023; 11(1):62. PMC: 10245617. DOI: 10.1186/s40364-023-00499-0. View

Urick M, Bell D . Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019; 19(9):510-521. PMC: 7446243. DOI: 10.1038/s41568-019-0177-x. View

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

Ding L, Wang R, Zheng Q, Shen D, Wang H, Lu Z . circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. J Exp Clin Cancer Res. 2022; 41(1):187. PMC: 9161465. DOI: 10.1186/s13046-022-02391-5. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Lee Y, Chen M, Pandolfi P . The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018; 19(9):547-562. DOI: 10.1038/s41580-018-0015-0. View

11.

Xue M, Dong L, Zhang H, Li Y, Qiu K, Zhao Z . METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation. J Hematol Oncol. 2024; 17(1):7. PMC: 10835888. DOI: 10.1186/s13045-024-01526-9. View

12.

Yang Y, Hu F, Xue M, Jia Y, Zheng Z, Li Y . Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease. Am J Physiol Cell Physiol. 2018; 316(3):C340-C352. DOI: 10.1152/ajpcell.00167.2018. View

13.

Kang S, Kim D, Kim K . BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. Int J Mol Sci. 2022; 23(18). PMC: 9504117. DOI: 10.3390/ijms231810730. View

14.

Liao W, Liu Y, Ying T, Shieh J, Hung Y, Lee H . Inhibitory Effects of Ursolic Acid on the Stemness and Progression of Human Breast Cancer Cells by Modulating Argonaute-2. Int J Mol Sci. 2023; 24(1). PMC: 9820512. DOI: 10.3390/ijms24010366. View

15.

Liu J, Eckert M, Harada B, Liu S, Lu Z, Yu K . mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018; 20(9):1074-1083. PMC: 6245953. DOI: 10.1038/s41556-018-0174-4. View

16.

Oliphant M, Vincent M, Galbraith M, Pandey A, Zaberezhnyy V, Rudra P . SIX2 Mediates Late-Stage Metastasis via Direct Regulation of and Induction of a Cancer Stem Cell Program. Cancer Res. 2019; 79(4):720-734. PMC: 6586234. DOI: 10.1158/0008-5472.CAN-18-1791. View

17.

You J, Wu Q, Li Y, Li X, Lin Z, Huang J . Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis. Oncol Rep. 2023; 50(1). PMC: 10285605. DOI: 10.3892/or.2023.8579. View

18.

Bu Z, Yang J, Zhang Y, Luo T, Fang C, Liang X . Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132-Loaded Fe-MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal Cancer. Adv Sci (Weinh). 2023; 10(23):e2301638. PMC: 10427397. DOI: 10.1002/advs.202301638. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

20.

Chen H, Ma J, Kong F, Song N, Wang C, Ma X . UPF1 contributes to the maintenance of endometrial cancer stem cell phenotype by stabilizing LINC00963. Cell Death Dis. 2022; 13(3):257. PMC: 8940903. DOI: 10.1038/s41419-022-04707-x. View